Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
1. A method for treating mild or moderate gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) each ranging from about 40 IU/kg to about 60 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII) ranging from about 20 to about 50 IU/kg.
2. The method of treatment of claim 1 , wherein the second dose of rVWF does not comprise rFVIII.
3. The method of treatment of claim 1 , wherein said rVWF is administered every 8 to 12 hours.
4. The method of claim 1 , wherein the subject is administered one dose of rVWF.
5. The method of treatment of claim 1 , wherein said subject has Type 3 VWD.
6. The method of treatment of claim 1 , wherein said subject has severe Type 1 VWD.
7. The method of treatment of claim 1 , wherein said subject has severe Type 2 VWD.
8. The method of claim 1 , wherein the subject had been treated for at least 1 bleeding event within the previous 12 months.
9. The method of claim 1 , wherein the subject had been treated for more than 1 bleeding event within the previous 12 months.
10. The method of treatment of claim 1 , wherein said rVWF and said rFVIII are administered sequentially.
11. A method for treating major or severe gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) each ranging from up to about 80 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII) ranging from about 20 to about 40 IU/kg.
12. The method of treatment of claim 11 , wherein the second dose of rVWF does not comprise rFVIII.
13. The method of treatment of claim 11 , wherein said rVWF is administered every 8 to 12 hours.
14. The method of claim 11 , wherein the subject is administered a single dose of rVWF.
15. The method of treatment of claim 11 , wherein said subject has Type 3 VWD.
16. The method of treatment of claim 11 , wherein said subject has severe Type 1 VWD.
17. The method of treatment of claim 11 , wherein said subject has severe Type 2 VWD.
18. The method of claim 11 , wherein the subject had been treated for at least 1 bleeding event within the previous 12 months.
19. The method of claim 11 , wherein the subject had been treated for more than 1 bleeding event within the previous 12 months.
20. The method of treatment of claim 11 , wherein said rVWF and said rFVIII are administered sequentially.